| Schedule of Long-Lived Assets by Geographic Location |
Long-lived assets, which consist of property and equipment, net, and operating lease right-of-use assets, net, as reported in the Company’s consolidated balance sheets, were attributed to the following geographic areas (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | December 31, | | | | | | | 2025 | | 2024 | | | United Kingdom | | | | $ | 127,658 | | | $ | 104,160 | | | | United States | | | | 455 | | | 891 | | | | Europe | | | | 390 | | | — | | | | | Total Long-Lived Assets | | | | $ | 128,503 | | | $ | 105,051 | | | |
|
| Schedule of Segment Profit or Loss, Including Significant Segment Expenses |
The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands): | | | | | | | | | | | | | | | December 31, | | | | 2025 | | 2024 | | | Total revenue, net | $ | 75,388 | | | $ | 10,120 | | | | | Less operating expenses: | | | | | | Cost of sales | (96,369) | | | (11,387) | | | | Research and clinical development | (56,848) | | | (37,831) | | | | | Product delivery | (21,739) | | | (78,428) | | | | Commercial and Medical affairs | (70,916) | | | (55,219) | | | | | Support functions | (80,899) | | | (66,300) | | | | Other segment expenses, net (1) | (19,161) | | | (2,381) | | | | | Total operating expenses | (345,932) | | | (251,546) | | | | | Operating loss | (270,544) | | | (241,426) | | | | | Other income, net | 515 | | | 220 | | | | Foreign exchange gains (losses) | 2,163 | | | (989) | | | | | Interest income | 18,980 | | | 32,355 | | | | Interest expense, net | (36,670) | | | (9,294) | | | | Income tax expense | (1,972) | | | (1,528) | | | | | Segment and consolidated net loss | $ | (287,528) | | | $ | (220,662) | | | | (1) Other segment expenses, net include U.K. research and development tax credits, depreciation, amortization and share-based compensation expenses. | | |
|